Insider · CIK 0001863624
Andrew Cittadine
Files at MNPR (Monopar Therapeutics). First filing -, latest -.
Andrew Cittadine files SEC Form 4 as COO at MNPR (Monopar Therapeutics). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Andrew Cittadine has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 25 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | MNPR Monopar Therapeutics | MOption exercise Common Stock | +4,384 | - | - | 59,998 | 11 d ago |
| Sep 30, 2026 | MNPR Monopar Therapeutics | FTax withholding Common Stock | -1,944 | $79.67 | $155k | 58,054 | 11 d ago |
| Sep 30, 2026 | MNPR Monopar Therapeutics | MOption exercise Restricted Stock Unitderivative | -4,384 | $0.00 | $0 | 35,115 | 11 d ago |
| Mar 31, 2026 | MNPR Monopar Therapeutics | MOption exercise Common Stock | +3,514 | - | - | 54,240 | Apr 2, 2026 |
| Mar 31, 2026 | MNPR Monopar Therapeutics | FTax withholding Common Stock | -1,571 | $54.79 | $86k | 52,669 | Apr 2, 2026 |
| Mar 31, 2026 | MNPR Monopar Therapeutics | MOption exercise Restricted Stock Unitderivative | -3,514 | $0.00 | $0 | 44,753 | Apr 2, 2026 |
| Dec 31, 2025 | MNPR Monopar Therapeutics | MOption exercise Common Stock | +4,326 | - | - | 52,615 | Jan 5, 2026 |
| Dec 31, 2025 | MNPR Monopar Therapeutics | FTax withholding Common Stock | -1,889 | $65.30 | $123k | 50,726 | Jan 5, 2026 |
| Dec 31, 2025 | MNPR Monopar Therapeutics | MOption exercise Restricted Stock Unitderivative | -4,326 | $0.00 | $0 | 48,267 | Jan 5, 2026 |
| Dec 2, 2025 | MNPR Monopar Therapeutics | AGrant or award Stock Optionsderivative | +8,969 | $0.00 | $0 | 8,969 | Dec 8, 2025 |
| Dec 2, 2025 | MNPR Monopar Therapeutics | AGrant or award Restricted Stock Unitsderivative | +13,919 | $0.00 | $0 | 52,593 | Dec 8, 2025 |
| Sep 30, 2025 | MNPR Monopar Therapeutics | MOption exercise Common Stock | +4,327 | - | - | 50,185 | Oct 2, 2025 |
| Sep 30, 2025 | MNPR Monopar Therapeutics | FTax withholding Common Stock | -1,896 | $81.67 | $155k | 48,289 | Oct 2, 2025 |
| Sep 30, 2025 | MNPR Monopar Therapeutics | MOption exercise Restricted Stock Unitsderivative | -4,327 | $0.00 | $0 | 38,674 | Oct 2, 2025 |
| Jun 30, 2025 | MNPR Monopar Therapeutics | MOption exercise Common Stock | +6,863 | - | - | 48,848 | Jul 2, 2025 |
| Jun 30, 2025 | MNPR Monopar Therapeutics | FTax withholding Common Stock | -2,990 | $35.78 | $107k | 45,858 | Jul 2, 2025 |
| Jun 30, 2025 | MNPR Monopar Therapeutics | MOption exercise Restricted Stock Unitsderivative | -6,863 | $0.00 | $0 | 43,001 | Jul 2, 2025 |
| Mar 31, 2025 | MNPR Monopar Therapeutics | MOption exercise Common Stock | +1,791 | - | - | 42,729 | Apr 2, 2025 |
| Mar 31, 2025 | MNPR Monopar Therapeutics | FTax withholding Common Stock | -744 | $36.41 | $27k | 41,985 | Apr 2, 2025 |
| Mar 31, 2024 | MNPR Monopar Therapeutics | MOption exercise Restricted Stock Unitsderivative | -1,791 | $0.00 | $0 | 49,864 | Apr 2, 2025 |
| Mar 4, 2025 | MNPR Monopar Therapeutics | AGrant or award Stock Optionsderivative | +43,445 | $0.00 | $0 | 43,445 | Mar 7, 2025 |
| Mar 4, 2025 | MNPR Monopar Therapeutics | AGrant or award Restricted Stock Unitsderivative | +40,581 | $0.00 | $0 | 51,655 | Mar 7, 2025 |
| Dec 31, 2024 | MNPR Monopar Therapeutics | MOption exercise Common Stock | +1,790 | - | - | 41,659 | Jan 2, 2025 |
| Dec 31, 2024 | MNPR Monopar Therapeutics | FTax withholding Common Stock | -721 | $22.00 | $16k | 40,938 | Jan 2, 2025 |
| Dec 31, 2024 | MNPR Monopar Therapeutics | MOption exercise Restricted Stock Unitsderivative | -1,790 | $0.00 | $0 | 11,074 | Jan 2, 2025 |
Questions about Andrew Cittadine
Answered from the filings on this page, as of the latest one.
Is Andrew Cittadine buying or selling?
Andrew Cittadine has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Andrew Cittadine's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Andrew Cittadine has 0.
Where does Andrew Cittadine file Form 4?
Andrew Cittadine has filed Form 4 at MNPR (Monopar Therapeutics) as Chief Operating Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.